HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2): Clinical and biological features and comparison with other acute myeloid leukemias with cytogenetic aberrations involving long arm of chromosome 3.

AbstractOBJECTIVES:
To compare, from a biological and clinical perspective, a significant group of patients with AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2) with another group of AML carrying different abnormalities of 3q at q21 or q26, the latter named as the AML abn(3q) group.
METHODS:
We developed a national survey with the participation of 13 Spanish hospitals, and retrospectively reviewed (from 1990 to 2010) these subtypes of AML. Fifty-five patients were collected: 35 with AML inv(3)/t(3;3) and 20 with AML abn(3q). A data collecting page that included main features at diagnosis, therapeutic approach and response, and survival variables, was distributed and completed.
RESULTS:
We did not find significant differences in sex, age, history of myelodysplastic syndrome or chemo-/radiotherapy, clinical presentation, WBC and platelet counts, hemoglobin level, blasts immunophenotype, serum lactatedehydrogenase, peripheral blood and bone marrow cellular dysplasia, and bone marrow biopsy findings. Although the association with monosomy 7 was significantly more frequent in AML inv(3)/t(3;3), this did not seem to influence outcome. The lack of response to the different modalities of treatment and the aggressive course of the disease were the standard in both cohorts of patients.
DISCUSSION:
Although not yet recognized by the World Health Organization classification, our results are in agreement with the findings of other authors, who include both subsets of AML together in the same group of adverse prognosis.
CONCLUSION:
In an attempt to simplify and bound entities with similar genetic background and clinical behavior, it would be desirable to bring together both subgroups of AML in a single section.
AuthorsJose Maria Raya, Taida Martín-Santos, Elisa Luño, Carmen Sanzo, Maria Luz Perez-Sirvent, Esperanza Such, José Tomás Navarro, Fuensanta Millá, Esther Alonso, Alicia Domingo, María Rozman, Marina Díaz-Beva, Ana Batlle, Sonia González-de-Villambrosia, Esperanza Tuset, Teresa Vallespí, Margarita Ortega, Alfredo Bermejo, Marisa Martín-Ramos, Valeria Peri, Francesc Solé, Lourdes Florensa, Grupo Español de Citología Hematológica (GECH), Working Group into the Sociedad Española de Hematología y Hemoterapia (SEHH)
JournalHematology (Amsterdam, Netherlands) (Hematology) Vol. 20 Issue 8 Pg. 435-441 (Sep 2015) ISSN: 1607-8454 [Electronic] England
PMID25680074 (Publication Type: Journal Article)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: